Satellos Bioscience Inc.
- MSLE
- NASDAQ
- Biotechnology
- Muscle Disease Therapeutics
- Biotech (MyoReGenX Platform)
$7.00
Today +8.70%Quote Oct 20, 2026, 08:00 PM UTC
−23.75%over the last month
Max drawdown −29.8%From 1-month high −23.7%3 months −28.4%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Satellos Bioscience
Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
18
Founded
2018
Market value
$108.2M
Quote Oct 20
Floor
$6.82
2.6% below price
Resistance
$7.23
3.2% above price
Price vs analyst targets
1 analyst
Lowest target
$18.00Highest target
$24.00
$18.00Highest target
$24.00
- Price $7.00
- Average target $20.75
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 196% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about MSLEPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free